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Introduction: The presence of the FLT3-ITD (internal tan-
dem duplication) mutation in patients with AML is associ-
ated with an adverse prognosis. Even with allogeneic
hematopoietic stem cell transplantation (HSCT), disease
relapse remains the biggest obstacle to success. Sorafenib is
an oral tyrosine kinase inhibitor which has been shown to
inhibit the FLT3 tyrosine kinase and have activity against
FLT3-ITD AML.
Methods: We are conducting a phase I clinical trial of
maintenance sorafenib in patients with FLT3-ITD AML after
HSCT. Any conditioning regimen and any donor source are
allowed. A dose escalation 3+3 cohort design was used to
deﬁne the maximum tolerated dose (MTD) of sorafenib after
HSCT with an additional 10 patients treated at the deﬁned
MTD. Sorafenib was initiated between days 45 and 120 after
HSCT and given continuously for twelve 28-day cycles. All
patients were proven to be in morphological CR after HSCT
and without any active acute graft-vs-host disease prior to
starting sorafenib.
Results: We have thus far enrolled 18 patients (CR1¼12,
CR2¼3, Refractory¼3). 10 patients underwent myeloablative
conditioning and 8 patients received reduced intensity con-
ditioning. Donors included matched related or unrelated
donors (n¼16), cord blood (n¼1), and haploidentical (n¼1).
12 patients were treated in the dose escalation phase: 200
mg BID (n¼3), 400 mg AM / 200 mg PM (n¼3), and 400 mg
BID (n¼6), and 6 patients have been treated so far on the
expansion phase. The MTD was established at 400 mg BID
with only one DLT observed (pericardial effusion) at the 400
mg BID dose level (the highest planned dose). Two patients
experienced early transplant-related mortality - one case of
idiopathic pneumonitis and one case of cirrhosis. Neither of
these deaths was deemed to be related to sorafenib. One
patient has stopped sorafenib after disease relapse and ﬁve
patients have stopped sorafenib due to toxicity (skin, GI,
weight loss, tongue swelling). No cases of grades II-IV acute
GVHD were observed after starting sorafenib and 1-year
cumulative incidence of chronic GVHD is 42% (95% CI 0.14,
0.69), which is similar to our historical controls. In the entire
cohort, there have been only two cases of disease relapse and
both were cases of primary refractory AML prior to HSCT.
Median follow-up for the 14 surviving patients is 10.9
months (range, 2.2-25.8) after transplant. One-year pro-
gression-free survival is 84% (95% CI 0.49, 0.96) and one-yearOS is 93% (95% CI 0.61, 0.99). No patients who underwent
HSCT in CR1 (n¼12) or CR2 (n¼3) have experienced relapse.
Conclusion: Sorafenib appears safe to use after HSCT for
patients with FLT3-ITD AML. Compared to historical results,
our preliminary results suggest promising progression-free
survival with no observed relapses in patients who under-
went HSCT in CR. Maintenance sorafenib after HSCT for
FLT3-ITD AML merits further investigation.214
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The nucleoside analog (NA) clofarabine (Clo) has improved
antileukemic efﬁcacy compared with ﬂudarabine (Flu),
commonly used with IV busulfan (Bu) in pretransplant con-
ditioning. In vitro studies of [Clo+Flu] with Bu in AML cells
showed higher synergistic cytotoxicity compared with
[Clo+Bu] or [Flu+Bu] combination.We studied [CloFlu] with
IV Bu in pretransplant conditioning for ML and MDS.
Methods: Patients were adaptively randomized (AR), based
on day +30- and chimerism-status: Arm I Clo:Flu 10:30 mg/
m2, Arm II 20:20 mg/m2, Arm III 30:10 mg/m2, and Arm IV
Clo only at 40 mg/m2. The NA were/was infused over 60 min
once daily for 4 days, on each day followed by Bu over 3
hours to an average daily AUC of 6,000 mM-min. GVHD-
prophylaxis was tacrolimus and mini-MTX. Recipients of
unrelated (MUD) or one antigen-mismatched related donor
cells received rabbit-ATG infused over 3 days for a total dose
of 4 mg/kg.
Results: 70 patients were treated, M:F 39:31, median age 46
years (6-59). 49 patients had AML, 8 had MDS and 13 had
CML. 29 patients had related donors while 41 had MUDs;
marrow was used in 24, blood progenitor cells in 46. Only 13
of 57 AML/MDS patients were in cytological CR, 44 had active
disease; all CML patients had advanced disease.
All evaluable patients engrafted and there were no sec-
ondary graft failures. Due to the AR, 25 patients were allo-
cated to arms I and II (lower Clo doses), and 45 to Arms III and
IV (higher Clo doses). Safety was acceptable with 100-day
non-relapse mortality of 4%. Grade 2-3 mucositis occurred in
half of the patients and there were no serious hepatic or
neurologic events. The minimum follow-up of surviving
patients was 26 months and there was no difference in
overall or progression-free survival based on CR-status at SCT
or whether patients had a MUD- or related donor graft.
We conclude that (1) [CloFlu] +IV Bu-based conditioning
therapy is safe and efﬁcacious in high-risk patients with ML/
MDS, (2) Clo is sufﬁciently immunosuppressive to be used
in pretransplant conditioning, and (3) the in vitro studies
which showed a superior cytotoxic synergy of [Clo+Flu+Bu]
compared with either [Clo+Bu] or [Flu+Bu] were supported
